137 related articles for article (PubMed ID: 35577545)
21. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
22. A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application.
García-Sánchez S; Collado-Borrell R; González-Haba E; Revuelta-Herrero JL; Escudero-Vilaplana V; Marzal-Alfaro MB; Sánchez-Fresneda MN; Mur-Mur A; Herranz A; Martín M; Sanjurjo M
Front Oncol; 2022; 12():889575. PubMed ID: 35756684
[TBL] [Abstract][Full Text] [Related]
23. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
24. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
25. Bone graft substitutes for the treatment of traumatic fractures of the extremities.
Hagen A; Gorenoi V; Schönermark MP
GMS Health Technol Assess; 2012; 8():Doc04. PubMed ID: 22984371
[TBL] [Abstract][Full Text] [Related]
26. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
27. Drug cost avoidance resulting from cancer clinical trials.
Bredin C; Eliasziw M; Syme R
Contemp Clin Trials; 2010 Nov; 31(6):524-9. PubMed ID: 20840876
[TBL] [Abstract][Full Text] [Related]
28. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
29. Estimating hospital inpatient cost-savings with sucroferric oxyhydroxide in patients on chronic hemodialysis in five European countries: a cost analysis.
Herrero JA; Salomone M; Ramirez de Arellano A; Schaufler T; Walpen S
J Med Econ; 2021; 24(1):1240-1247. PubMed ID: 34761724
[TBL] [Abstract][Full Text] [Related]
30. Clinical research activities during COVID-19: the point of view of a promoter of academic clinical trials.
Valmorri L; Vertogen B; Zingaretti C; Miserocchi A; Volpi R; Clemente A; Bondi I; Valli I; Rudnas B; Martinelli G; Nanni O
BMC Med Res Methodol; 2021 Apr; 21(1):91. PubMed ID: 33931012
[TBL] [Abstract][Full Text] [Related]
31. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
32. Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact.
Sánchez Martínez DA; Salas-Lucia F; Jiang H; Ruiz-Carreño P; Alonso Romero JL
BMC Health Serv Res; 2022 Jul; 22(1):948. PubMed ID: 35883128
[TBL] [Abstract][Full Text] [Related]
33. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
34. Retrospective analysis of gastric cancer management in a real-world setting: a single-institution experience.
Monti M; Massa I; Foca F; Morgagni P; Framarini M; Passardi A; Falcini F; Frassineti GL
Tumori; 2020 Apr; 106(2):165-171. PubMed ID: 32167020
[TBL] [Abstract][Full Text] [Related]
35. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
[TBL] [Abstract][Full Text] [Related]
36. An estimate of the cost of conducting phase II trials in lung cancer.
Evans WK; Dahrouge S; Stapleton J; Quinn C; Pollock D; Waterfield B; Lister D; Hansel F; Smith A
Lung Cancer; 2000 May; 28(2):85-95. PubMed ID: 10717326
[TBL] [Abstract][Full Text] [Related]
37. The economic impact of compassionate use of medicines.
Jommi C; Pantellini F; Stagi L; Verykiou M; Cavazza M
BMC Health Serv Res; 2021 Dec; 21(1):1303. PubMed ID: 34863155
[TBL] [Abstract][Full Text] [Related]
38. Cancer Clinical Trials: Treatment Costs Associated With a Spanish National Health System Institution.
Capdevila F; Vera R; Ochoa P; Galbete A; Sanchez-Iriso E
Ther Innov Regul Sci; 2019 Sep; 53(5):641-647. PubMed ID: 30428709
[TBL] [Abstract][Full Text] [Related]
39. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach.
Hamblin S; Rumbaugh K; Miller R
J Trauma Acute Care Surg; 2012 Dec; 73(6):1484-90. PubMed ID: 23064610
[TBL] [Abstract][Full Text] [Related]
40. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
